ナミキ商事株式会社 医薬品及び創薬化学品の専門商社

医薬品及び創薬化学品の専門商社

検索検索

新着情報News

【CUSABIO】Exciting! CUSABIO Quarterly Citation: 918 papers, 5000+ impact factor!

  • 2024/04/24
  • サプライヤニュース

新着情報一覧へ

 

We partner with Namiki Shoji to advance scientific innovation.

Thank you for your continuous support to CUSABIO! In the first quarter of 2024, CUSABIO products published more than 918 articles with a cumulative impact factor of 5000+! The total number of articles has reached 22,500! Thank you for choosing CUSABIO reagent during your scientific research journey. Thank you again for your trust and support. We will continue to work hard to provide you with better products and services! Now let's share our wonderful research results~

CUSABIO Quarterly Top 10 Recommended Publications
Top 1

Article Title: Bone-targeting engineered small extracellular vesicles carrying anti-miR-6359-CGGGAGC prevent valproic acid-induced bone loss

Journal Name: Signal transduction and targeted therapy

Impact Factor: 39.3

CUSABIO Citation Product:

CSB-E08492m: Mouse tartrate-resistant acid phosphatase 5b(TRACP-5b) ELISA Kit

CSB-E16211m: Mouse C-telopeptide of type Ⅱ collagen(CTX-Ⅱ) ELISA Kit

CSB-E12775m: Mouse procollagen Ⅰ N-terminal peptide,PⅠNP ELISA Kit

CSB-E11914m: Mouse Bone-specific alkaline phosphatase (BALP) ELISA kit

Research Highlights:

The study deepening our understanding of the underlying mechanism and treatment strategies for VPA-induced bone loss, confirmed that VPA treatment was associated with decreased bone mass and bone mineral density (BMD) in both patients and mice. This effect was attributed to VPA-induced elevation in osteoclast formation and activity. However, currently, there are no medications that can effectively treat VPA-induced bone loss. And the study confirmed that the E-sEVs exhibited decent bone/osteoclast precursor targeting and exerted protective therapeutic effects on VPA-induced bone loss, but not on ovariectomy (OVX) and glucocorticoid-induced osteoporotic models.

Top 2

Article Title: Multi-cohort validation of Ascore: an anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer

Journal Name: Molecular cancer

Impact Factor: 37.3

CUSABIO Citation Product:

CSB-PA007648LA01HU: EMP1 Antibody

CSB-PA009627LA01HU: GNLY Antibody

Research Highlights:

Bladder cancer ranks as the 10th most common cancer worldwide, with deteriorating prognosis as the disease advances.While immune checkpoint inhibitors (ICIs) have shown promise in clinical therapy in both operable and advanced bladder cancer, identifying patients who will respond is challenging.Anoikis, a specialized form of cell death that occurs when cells detach from the extracellular matrix, is closely linked to tumor progression.The study introduces Ascore as a novel, robust prognostic biomarker for bladder cancer, offering a new tool for enhancing immunotherapy decisions and contributing to the tailored treatment approaches in this field.

Top 3

Article Title: Carnosine regulation of intracellular pH homeostasis promotes lysosome-dependent tumor immunoevasion

Journal Name: Nature immunology

Impact Factor: 30.5

CUSABIO Citation Product:

CSB-EL012895HU: Human Galectin-9(LGALS9) ELISA kit

Research Highlights:

Tumor cells and surrounding immune cells undergo metabolic reprogramming, leading to an acidic tumor microenvironment.However, it is unclear how tumor cells adapt to this acidic stress during tumor progression.The study show that carnosine, a mobile buffering metabolite that accumulates under hypoxia in tumor cells, regulates intracellular pH homeostasis and drives lysosome-dependent tumor immune evasion.A previously unrecognized isoform of carnosine synthase, CARNS2, promotes carnosine synthesis under hypoxia.These findings indicate an unconventional mechanism for pHi regulation in cancer cells and demonstrate how lysosome contributes to immune evasion, thus providing a basis for development of combined therapeutic strategies against hepatocellular carcinoma that exploit disrupted pHi homeostasis with immune checkpoint blockade.

Top 4

Article Title: Gene engineered exosome reverses T cell exhaustion in cancer immunotherapy

Journal Name: Bioactive materials

Impact Factor: 18.9

CUSABIO Citation Product:

CSB-E04600m: Mouse Interleukin 12,IL-12/P70 ELISA KIT

Research Highlights:

Cancer patients by immune checkpoint therapy have achieved long-term remission, with no recurrence of clinical symptoms of cancer for many years. Nevertheless, more than half of cancer patients are not responsive to this therapy due to immune exhaustion. The study report a novel gene engineered exosome which is rationally designed by engineering PD1 gene and simultaneously enveloping an immune adjuvant imiquimod (PD1-Imi Exo) for boosting response of cancer immune checkpoint blockage therapy, and which also could be used for reversing T cell exhaustion in cancer immunotherapy. This study also offers a promising new strategy for enhancing PD1/PDL1 therapeutic efficacy, preventing tumor recurrence or metastasis after surgery by rebuilding the patients' immunity, thus consolidating the overall prognosis.

Top 5

Article Title: Spatiotemporal and direct capturing global substrates of lysine-modifying enzymes in living cells

Journal Name: Nature communications

Impact Factor: 16.6

CUSABIO Citation Product:

CSB-PA359270HA01EGX: ftsZ Antibody

Research Highlights:

Protein-modifying enzymes regulate the dynamics of myriad post-translational modification (PTM) substrates.Precise characterization of enzyme-substrate associations is essential for the molecular basis of cellular function and phenotype.Methods for direct capturing global substrates of protein-modifying enzymes in living cells are with many challenges, and yet largely unexplored. The study report a strategy to directly capture substrates of lysine-modifying enzymes via PTM-acceptor residue crosslinking in living cells, enabling global profiling of substrates of PTM-enzymes and validation of PTM-sites in a straightforward manner.

Top 6

Article Title: TYK2 signaling promotes the development of autoreactive CD8+ cytotoxic T lymphocytes and type 1 diabetes

Journal Name: Nature communications

Impact Factor: 16.6

CUSABIO Citation Product:

CSB-E10369m: Mouse insulin autoantibodies(IAA) ELISA Kit

Research Highlights:

Tyrosine kinase 2 (TYK2), a member of the JAK family, has attracted attention as a potential therapeutic target for autoimmune diseases. However, the role of TYK2 in CD8+ T cells and autoimmune type 1 diabetes (T1D) is poorly understood. The study generate Tyk2 gene knockout non-obese diabetes (NOD) mice and demonstrate that the loss of Tyk2 inhibits the development of autoreactive CD8+ T-BET+ cytotoxic T lymphocytes (CTLs) by impairing IL-12 signaling in CD8+ T cells and the CD8+ resident dendritic cell-driven cross-priming of CTLs in the pancreatic lymph node (PLN). Thus, our study reveals the diverse roles of TYK2 in driving the pathogenesis of T1D.

Top 7

Article Title: Eosinophils preserve bone homeostasis by inhibiting excessive osteoclast formation and activity via eosinophil peroxidase

Journal Name: Nature communications

Impact Factor: 16.6

CUSABIO Citation Product:

CSB-E11729h: Human eosinophil cationic protein,ECP ELISA Kit

Research Highlights:

This article revealed that eosinophil peroxidase (EPX) plays an important role in the maintenance of bone tissue homeostasis, and inhibited overactive osteoblasts by releasing Eosinophil peroxidase (EPX), so as to maintain bone health.

Top 8

Article Title: Redox-responsive polymer micelles co-encapsulating immune checkpoint inhibitors and chemotherapeutic agents for glioblastoma therapy

Journal Name: Nature communications

Impact Factor: 16.6

CUSABIO Citation Product:

CSB-E06949Rb: Rabbit Immunoglobulin G,IgG ELISA Kit

Research Highlights:

Immunotherapy with immune checkpoint blockade (ICB) for glioblastoma (GBM) is promising but its clinical efficacy is seriously challenged by the blood-tumor barrier (BTB) and immunosuppressive tumor microenvironment.The ICB efficacy is enhanced by the aPD-L1 and PTX combination with suppression of primary and recurrent GBM, accumulation of cytotoxic T lymphocytes, and induction of long-lasting immunological memory in the orthotopic GBM-bearing mice.The co-encapsulation approach facilitating efficient antibody delivery and combining with chemotherapeutic agent-induced ICD demonstrate that the chemo-immunotherapy might reprogram local immunity to empower immunotherapy against GBM.

Top 9

Article Title: Multigenerational paternal obesity enhances the susceptibility to male subfertility in offspring via Wt1 N6-methyladenosine modification

Journal Name: Nature communications

Impact Factor: 16.6

CUSABIO Citation Product:

CSB-E07891m: Mouse Vitamin A,VA ELISA Kit

Research Highlights:

There is strong evidence that obesity is a risk factor for poor semen quality.However, the effects of multigenerational paternal obesity on the susceptibility to cadmium (a reproductive toxicant)-induced spermatogenesis disorders in offspring remain unknown. Collectively, these results indicate that multigenerational paternal obesity enhances the susceptibility of the offspring to spermatogenesis disorders by increasing METTL3-mediated Wt1 N6-methyladenosine modification.

Top 10

Article Title: Ubiquitin ligase RNF20 coordinates sequential adipose thermogenesis with brown and beige fat-specific substrates

Journal Name: Nature communications

Impact Factor: 16.6

CUSABIO Citation Product:

CSB-PA01985A0Rb: SDHA Antibody

Research Highlights:

In mammals, brown adipose tissue (BAT) and inguinal white adipose tissue (iWAT) execute sequential thermogenesis to maintain body temperature during cold stimuli.BAT rapidly generates heat through brown adipocyte activation, and further iWAT gradually stimulates beige fat cell differentiation upon prolonged cold challenges. However, fat depot-specific regulatory mechanisms for thermogenic activation of two fat depots are poorly understood. The study demonstrate that E3 ubiquitin ligase RNF20 orchestrates adipose thermogenesis with BAT- and iWAT-specific substrates. Moreover, upon prolonged cold stimuli, iWAT RNF20 is gradually upregulated to promote de novo beige adipogenesis. Together, current findings propose fat depot-specific regulatory mechanisms for temporal activation of adipose thermogenesis.

CUSABIO(クサバイオ)社について

設立
2007年
社員数
700名
本社所在地
中国 武漢
URL
https://www.cusabio.com/

CUSABIO社は抗体、タンパク質、ELISA Kitをはじめとした研究用試薬のご提供およびサービスに特化したバイオテクノロジーサプライヤーです。
CUSABIO社には、博士号と修士号を取得した科学者で構成される研究開発チームがあり、従業員の 60% 以上が技術チームの出身で、うち 20% が博士号、50% が修士号を取得しております。
研究チームは国内の著名な機関から集まり、タンパク質、抗体、ELISA キットの開発に長年の経験を持っております。
主に抗体やタンパク質、ELISA Kit、ペプチドなどを取り扱っており、世界中のお客様からその品質の高さやアフターサポートの手厚さなどでご好評をいただいております。

特徴
    • 6000m2を超えるR&Dセンター

ご不明点等ございましたら、お気軽にお問い合わせください。

お問い合わせ